Literature DB >> 15017200

Histology in mixed germ cell tumors. Is there a favorite pairing?

Ashraf A Mosharafa1, Richard S Foster, Bradley C Leibovich, Thomas M Ulbright, Richard Bihrle, Lawrence H Einhorn, John P Donohue.   

Abstract

PURPOSE: Mixed germ cell tumors account for approximately 30% to 50% of testicular tumors. To our knowledge a systematic review with statistical analysis of the associations of histological subtypes in mixed germ cell tumors has not been done previously. It was our impression that such associations exist. Delineating concordant histological types may provide insight into the ontogeny of testicular tumors and also have important clinical implications.
MATERIALS AND METHODS: We retrospectively reviewed the testis cancer data base at our institution. The primary tumor of orchiectomy specimens was examined in 2589 patients. Of these patients mixed histology was noted in 1765 (68.2%). ORs were calculated for all possible combinations of teratoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma and seminoma. In addition, we evaluated the association of various histological types with teratoma at post-chemotherapy retroperitoneal lymph node dissection.
RESULTS: Of 10 possible combinations of histological types in the primary tumor, positive correlations were noted in 4. The strongest correlation was found between teratoma and yolk sac tumor (OR 2.58, p <0.001). Teratoma or yolk sac tumor in the testis was associated with teratoma in the pathology specimen at post-chemotherapy retroperitoneal lymph node dissection.
CONCLUSIONS: The strongest associations of histological subtypes in mixed germ cell tumors were seen between yolk sac tumor and teratoma. Similar associations are seen in late relapse and in some cases of prepubertal tumors. Further study of these associations may prove valuable in understanding the biology and clinical behavior of germ cell tumors.

Entities:  

Mesh:

Year:  2004        PMID: 15017200     DOI: 10.1097/01.ju.0000116841.30826.85

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Teratocarcinoma in a non seminomatous, mixed germ cell tumour of the testis-a rare entity.

Authors:  Gayathri Malavalli; Shilpa Karra; Bharathi Muniyappa
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  "Off-Label" Usage of Testicular Self-Examination (TSE): Benefits Beyond Cancer Detection.

Authors:  Michael J Rovito; James E Leone; Chase T Cavayero
Journal:  Am J Mens Health       Date:  2015-05-19

3.  Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors.

Authors:  Masatomo Nishikawa; Hideaki Miyake; Mototsugu Muramaki; Masato Fujisawa
Journal:  Med Oncol       Date:  2014-10-24       Impact factor: 3.064

4.  Testicular seminomatous mixed germ cell tumor with choriocarcinoma and teratoma with secondary somatic malignancy: a case report.

Authors:  Amandeep Aneja; Siddharth Bhattacharyya; Jack Mydlo; Susan Inniss
Journal:  J Med Case Rep       Date:  2014-01-01

5.  MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors.

Authors:  Matteo Rossi; David Colecchia; Gennaro Ilardi; Mario Acunzo; Giovanni Nigita; Federica Sasdelli; Angela Celetti; Angela Strambi; Stefania Staibano; Carlo Maria Croce; Mario Chiariello
Journal:  Oncotarget       Date:  2016-04-12

6.  A Review in Management of Testicular Cancer: Single Center Review.

Authors:  Ammar Hameed; Bob White; Frank Chinegwundoh; Ali Thwaini; Ajay Pahuja
Journal:  World J Oncol       Date:  2011-06-08

7.  Testicular Mixed Germ Cell Tumor Combined with Malignant Transformation to Chondrosarcoma: A Very Rare and Aggressive Disease.

Authors:  Mohammad Alrehaili; Emad Tashkandi
Journal:  Am J Case Rep       Date:  2020-06-26

8.  Predictors of viable germ cell tumor in postchemotherapeutic residual retroperitoneal masses.

Authors:  Khalid Al Othman; Naif Al Hathal; Alaa Mokhtar
Journal:  Urol Ann       Date:  2014-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.